Shopping Cart 0
Cart Subtotal
USD 0

Charles River Laboratories International Inc (CRL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Charles River Laboratories International Inc (Charles River) is a contract research organization (CRO) that provides essential products and services to accelerate the research, drug discovery and development. It offers various basic research, drug discovery and safety assessment services. The organization also offers clinical, manufacturing and operations and staffing support. It focuses on providing solutions targeted against therapeutic areas of cardiovascular, central nervous system, metabolic inflammation, oncology, ophthalmology, respiratory disease and musculoskeletal disease. Charles River caters its products and services to pharmaceutical and biotechnology companies, government agencies, as well as leading hospitals and academic institutions. It operates through its network facilities located worldwide. Charles River is headquartered in Wilmington, Massachusetts, the US.

Charles River Laboratories International Inc (CRL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Charles River Laboratories International Inc, Medical Devices Deals, 2012 to YTD 2018 12

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deal Details 17

Asset Purchase 17

WIL Research Acquires Pharma Services Business Of Ricerca Biosciences 17

Venture Financing 18

KPI Therapeutics Raises USD1.6 Million in Venture Financing 18

Partnerships 19

Charles River Labs and Distributed Bio Enter into Partnership 19

HemaCare and Charles River Laboratories Enter into Partnership 20

Inscopix Enters into Partnership with Brains On-Line 21

Nimbus Therapeutics Enters into Agreement with Charles River Laboratories International 22

Charles River Laboratories International Expands its Agreement with Chiesi Farmaceutici 23

Charles River Laboratories International Extends Agreement with Genentech 24

Charles River Labs Enters into Agreement with Tri-Institutional Therapeutics Discovery Institute 25

Moderna Therapeutics Enters into Agreement with Charles River Labs 26

Charles River Labs Enters into Agreement with BioMotiv 27

Eisai Extends Research Agreement with Charles River Labs 28

Charles River Labs Expands Agreement with Michael J. Fox Foundation for Parkinson's Research 29

Charles River Labs Enters into Agreement with Antabio 30

Charles River Labs Enters into Agreement with Pcovery 31

Charles River Labs Enters into Agreement with British Columbia Cancer Agency 32

Charles River Lab Extends Co-Development Agreement with CHDI Foundation 33

BioFocus Enters Into Drug Discovery Agreement With Boehringer Ingelheim 34

MPI Research Enters Into Agreement With inviCRO And 3D Imaging For Drug Discovery And Development 35

BioFocus Extends Agreement With Michael J. Fox Foundation For Parkinson's Disease 36

Applied StemCell Enters Into Distribution Agreement With Charles River Labs For Genetically Modified Targatt Mouse 37

BioFocus Enters Into Agreement With ChanTest 38

Charles River Labs Expands its Agreement with AstraZeneca 39

Ono Pharma Enters Into Discovery Agreement With BioFocus For CNS Drugs 40

Activiomics Enters Into Drug Discovery Agreement With BioFocus 41

Ono Pharma Enters Into Drug Discovery Agreement With BioFocus 42

Almirall Enters Into Integrated Drug Discovery Collaboration With BioFocus 43

Licensing Agreements 44

EMD Millipore Enters Into Licensing Agreement With Charles River Labs For TrueSpike Technology 44

Equity Offering 45

Charles River Laboratories International Plans to Raise Funds in Public Offering of Securities 45

Charles River Labs to Invest USD10 Million in BioMotiv 46

Debt Offering 47

Charles River Lab Raises USD500 Million in Private Placement of 5.5% Senior Notes Due 2026 47

Acquisition 48

Charles River Laboratories Acquires MPI Research for USD800 Million 48

Charles River Labs Acquires KWS BioTest for USD24.3 Million 50

Charles River Laboratories Acquires Brains On-Line 51

Quotient Clinical Acquires QS Pharma from Charles River Labs 52

Charles River Laboratories Acquires Agilux Laboratories for USD64.9 Million 53

Charles River Labs Acquires Blue Stream Labs 54

Charles River Laboratories Acquires WIL Research for USD604.8 Million 55

Charles River Labs Acquires Oncotest 57

Charles River Labs Acquires ChanTest from Ampersand Capital for USD59.2 Million 58

MPI Research Acquired Jasper Clinic, Clinical Research Organization 59

Charles River Laboratories Acquires VivoPath 60

Charles River Labs Completes Acquisition Of BioFocus And Argenta Discovery From Galapagos For USD191.8 Million 61

Charles River Labs Acquires Brass 63

Charles River Labs Completes Acquisition Of 75% Stake In Vital River Labs For USD 27 Million 64

Charles River Plans Sale Of The Company 65

Charles River Laboratories International Inc-Key Competitors 66

Charles River Laboratories International Inc-Key Employees 67

Charles River Laboratories International Inc-Locations And Subsidiaries 69

Head Office 69

Other Locations & Subsidiaries 69

Recent Developments 73

Strategy And Business Planning 73

Jun 19, 2018: Charles River Laboratories Joins UConn TIP 73

May 01, 2018: Charles River Laboratories Expands Services for Early Discovery Screening 74

Financial Announcements 75

Nov 07, 2018: Charles River Laboratories announces third-quarter 2018 results 75

Aug 08, 2018: Charles River Laboratories announces second-quarter 2018 results from continuing operations 77

May 10, 2018: Charles River Laboratories Announces First-Quarter 2018 Results from Continuing Operations 79

Feb 13, 2018: Charles River Laboratories Announces Fourth-Quarter 2017 Financial Results 81

Nov 09, 2017: Charles River Laboratories Announces Third-Quarter 2017 Results from Continuing Operations 84

Aug 09, 2017: Charles River Laboratories Announces Second-Quarter 2017 Results from Continuing Operations 86

May 10, 2017: Charles River Laboratories Announces First-Quarter 2017 Results from Continuing Operations 88

Feb 14, 2017: Charles River Laboratories Announces Fourth-Quarter and Full-Year 2016 Results from Continuing Operations and Provides 2017 Guidance 90

Corporate Communications 93

Feb 13, 2018: Charles River Laboratories Announces Executive Management Appointments 93

Jan 16, 2018: Charles River Laboratories Adds Jean-Paul Mangeolle to Board of Directors 94

Jul 05, 2017: Charles River Laboratories Adds Martin Mackay, Ph.D. to Board of Directors 95

Government and Public Interest 96

Oct 16, 2018: Charles River Laboratories awarded five-year, USD 95.7 million contract by the National Institute of Allergy and Infectious Diseases 96

Product News 97

Apr 03, 2017: Charles River Laboratories Announces Launch of Triple-Immunodeficient Mouse Model for Oncology Research 97

Other Significant Developments 98

Apr 25, 2018: Extending Biomarker Sensitivity with the Quanterix Simoa HD-1 98

Mar 08, 2018: Charles River Laboratories Makes Expansions to Global Biologics Infrastructure 99

Feb 21, 2018: Charles River Laboratories Announces New Tumor Model Compendium 100

Dec 06, 2017: Charles River Adds ERS License to CRISPR/Cas9 Service Offering 101

May 16, 2017: Charles River Laboratories Announces Updates to Oncology Business 102

Appendix 103

Methodology 103

About GlobalData 103

Contact Us 103

Disclaimer 103


List Of Figure

List of Figures

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Charles River Laboratories International Inc, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Charles River Laboratories International Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Charles River Laboratories International Inc, Medical Devices Deals, 2012 to YTD 2018 12

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

WIL Research Acquires Pharma Services Business Of Ricerca Biosciences 17

KPI Therapeutics Raises USD1.6 Million in Venture Financing 18

Charles River Labs and Distributed Bio Enter into Partnership 19

HemaCare and Charles River Laboratories Enter into Partnership 20

Inscopix Enters into Partnership with Brains On-Line 21

Nimbus Therapeutics Enters into Agreement with Charles River Laboratories International 22

Charles River Laboratories International Expands its Agreement with Chiesi Farmaceutici 23

Charles River Laboratories International Extends Agreement with Genentech 24

Charles River Labs Enters into Agreement with Tri-Institutional Therapeutics Discovery Institute 25

Moderna Therapeutics Enters into Agreement with Charles River Labs 26

Charles River Labs Enters into Agreement with BioMotiv 27

Eisai Extends Research Agreement with Charles River Labs 28

Charles River Labs Expands Agreement with Michael J. Fox Foundation for Parkinson's Research 29

Charles River Labs Enters into Agreement with Antabio 30

Charles River Labs Enters into Agreement with Pcovery 31

Charles River Labs Enters into Agreement with British Columbia Cancer Agency 32

Charles River Lab Extends Co-Development Agreement with CHDI Foundation 33

BioFocus Enters Into Drug Discovery Agreement With Boehringer Ingelheim 34

MPI Research Enters Into Agreement With inviCRO And 3D Imaging For Drug Discovery And Development 35

BioFocus Extends Agreement With Michael J. Fox Foundation For Parkinson's Disease 36

Applied StemCell Enters Into Distribution Agreement With Charles River Labs For Genetically Modified Targatt Mouse 37

BioFocus Enters Into Agreement With ChanTest 38

Charles River Labs Expands its Agreement with AstraZeneca 39

Ono Pharma Enters Into Discovery Agreement With BioFocus For CNS Drugs 40

Activiomics Enters Into Drug Discovery Agreement With BioFocus 41

Ono Pharma Enters Into Drug Discovery Agreement With BioFocus 42

Almirall Enters Into Integrated Drug Discovery Collaboration With BioFocus 43

EMD Millipore Enters Into Licensing Agreement With Charles River Labs For TrueSpike Technology 44

Charles River Laboratories International Plans to Raise Funds in Public Offering of Securities 45

Charles River Labs to Invest USD10 Million in BioMotiv 46

Charles River Lab Raises USD500 Million in Private Placement of 5.5% Senior Notes Due 2026 47

Charles River Laboratories Acquires MPI Research for USD800 Million 48

Charles River Labs Acquires KWS BioTest for USD24.3 Million 50

Charles River Laboratories Acquires Brains On-Line 51

Quotient Clinical Acquires QS Pharma from Charles River Labs 52

Charles River Laboratories Acquires Agilux Laboratories for USD64.9 Million 53

Charles River Labs Acquires Blue Stream Labs 54

Charles River Laboratories Acquires WIL Research for USD604.8 Million 55

Charles River Labs Acquires Oncotest 57

Charles River Labs Acquires ChanTest from Ampersand Capital for USD59.2 Million 58

MPI Research Acquired Jasper Clinic, Clinical Research Organization 59

Charles River Laboratories Acquires VivoPath 60

Charles River Labs Completes Acquisition Of BioFocus And Argenta Discovery From Galapagos For USD191.8 Million 61

Charles River Labs Acquires Brass 63

Charles River Labs Completes Acquisition Of 75% Stake In Vital River Labs For USD 27 Million 64

Charles River Plans Sale Of The Company 65

Charles River Laboratories International Inc, Key Competitors 66

Charles River Laboratories International Inc, Key Employees 67

Charles River Laboratories International Inc, Subsidiaries 69

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Charles River Laboratories International Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Charles River Laboratories International Inc (Charles River) is a contract research organization (CRO) that provides essential products and services to accelerate the research, drug discovery and development. It offers various basic research, drug discovery and safety assessment services. The organization also offers clinical, manufacturing and operations and staffing support. It focuses on providing solutions targeted against therapeutic areas of cardiovascular, central nervous system, metabolic inflammation, oncology, ophthalmology, respiratory disease and musculoskeletal disease. Charles River caters its products and services to pharmaceutical and biotechnology companies, government agencies, as well as leading hospitals and academic institutions. It operates through its network facilities located worldwide. Charles River is headquartered in Wilmington, Massachusetts, the US.

Charles River Laboratories International Inc (CRL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Charles River Laboratories International Inc, Medical Devices Deals, 2012 to YTD 2018 12

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deal Details 17

Asset Purchase 17

WIL Research Acquires Pharma Services Business Of Ricerca Biosciences 17

Venture Financing 18

KPI Therapeutics Raises USD1.6 Million in Venture Financing 18

Partnerships 19

Charles River Labs and Distributed Bio Enter into Partnership 19

HemaCare and Charles River Laboratories Enter into Partnership 20

Inscopix Enters into Partnership with Brains On-Line 21

Nimbus Therapeutics Enters into Agreement with Charles River Laboratories International 22

Charles River Laboratories International Expands its Agreement with Chiesi Farmaceutici 23

Charles River Laboratories International Extends Agreement with Genentech 24

Charles River Labs Enters into Agreement with Tri-Institutional Therapeutics Discovery Institute 25

Moderna Therapeutics Enters into Agreement with Charles River Labs 26

Charles River Labs Enters into Agreement with BioMotiv 27

Eisai Extends Research Agreement with Charles River Labs 28

Charles River Labs Expands Agreement with Michael J. Fox Foundation for Parkinson's Research 29

Charles River Labs Enters into Agreement with Antabio 30

Charles River Labs Enters into Agreement with Pcovery 31

Charles River Labs Enters into Agreement with British Columbia Cancer Agency 32

Charles River Lab Extends Co-Development Agreement with CHDI Foundation 33

BioFocus Enters Into Drug Discovery Agreement With Boehringer Ingelheim 34

MPI Research Enters Into Agreement With inviCRO And 3D Imaging For Drug Discovery And Development 35

BioFocus Extends Agreement With Michael J. Fox Foundation For Parkinson's Disease 36

Applied StemCell Enters Into Distribution Agreement With Charles River Labs For Genetically Modified Targatt Mouse 37

BioFocus Enters Into Agreement With ChanTest 38

Charles River Labs Expands its Agreement with AstraZeneca 39

Ono Pharma Enters Into Discovery Agreement With BioFocus For CNS Drugs 40

Activiomics Enters Into Drug Discovery Agreement With BioFocus 41

Ono Pharma Enters Into Drug Discovery Agreement With BioFocus 42

Almirall Enters Into Integrated Drug Discovery Collaboration With BioFocus 43

Licensing Agreements 44

EMD Millipore Enters Into Licensing Agreement With Charles River Labs For TrueSpike Technology 44

Equity Offering 45

Charles River Laboratories International Plans to Raise Funds in Public Offering of Securities 45

Charles River Labs to Invest USD10 Million in BioMotiv 46

Debt Offering 47

Charles River Lab Raises USD500 Million in Private Placement of 5.5% Senior Notes Due 2026 47

Acquisition 48

Charles River Laboratories Acquires MPI Research for USD800 Million 48

Charles River Labs Acquires KWS BioTest for USD24.3 Million 50

Charles River Laboratories Acquires Brains On-Line 51

Quotient Clinical Acquires QS Pharma from Charles River Labs 52

Charles River Laboratories Acquires Agilux Laboratories for USD64.9 Million 53

Charles River Labs Acquires Blue Stream Labs 54

Charles River Laboratories Acquires WIL Research for USD604.8 Million 55

Charles River Labs Acquires Oncotest 57

Charles River Labs Acquires ChanTest from Ampersand Capital for USD59.2 Million 58

MPI Research Acquired Jasper Clinic, Clinical Research Organization 59

Charles River Laboratories Acquires VivoPath 60

Charles River Labs Completes Acquisition Of BioFocus And Argenta Discovery From Galapagos For USD191.8 Million 61

Charles River Labs Acquires Brass 63

Charles River Labs Completes Acquisition Of 75% Stake In Vital River Labs For USD 27 Million 64

Charles River Plans Sale Of The Company 65

Charles River Laboratories International Inc-Key Competitors 66

Charles River Laboratories International Inc-Key Employees 67

Charles River Laboratories International Inc-Locations And Subsidiaries 69

Head Office 69

Other Locations & Subsidiaries 69

Recent Developments 73

Strategy And Business Planning 73

Jun 19, 2018: Charles River Laboratories Joins UConn TIP 73

May 01, 2018: Charles River Laboratories Expands Services for Early Discovery Screening 74

Financial Announcements 75

Nov 07, 2018: Charles River Laboratories announces third-quarter 2018 results 75

Aug 08, 2018: Charles River Laboratories announces second-quarter 2018 results from continuing operations 77

May 10, 2018: Charles River Laboratories Announces First-Quarter 2018 Results from Continuing Operations 79

Feb 13, 2018: Charles River Laboratories Announces Fourth-Quarter 2017 Financial Results 81

Nov 09, 2017: Charles River Laboratories Announces Third-Quarter 2017 Results from Continuing Operations 84

Aug 09, 2017: Charles River Laboratories Announces Second-Quarter 2017 Results from Continuing Operations 86

May 10, 2017: Charles River Laboratories Announces First-Quarter 2017 Results from Continuing Operations 88

Feb 14, 2017: Charles River Laboratories Announces Fourth-Quarter and Full-Year 2016 Results from Continuing Operations and Provides 2017 Guidance 90

Corporate Communications 93

Feb 13, 2018: Charles River Laboratories Announces Executive Management Appointments 93

Jan 16, 2018: Charles River Laboratories Adds Jean-Paul Mangeolle to Board of Directors 94

Jul 05, 2017: Charles River Laboratories Adds Martin Mackay, Ph.D. to Board of Directors 95

Government and Public Interest 96

Oct 16, 2018: Charles River Laboratories awarded five-year, USD 95.7 million contract by the National Institute of Allergy and Infectious Diseases 96

Product News 97

Apr 03, 2017: Charles River Laboratories Announces Launch of Triple-Immunodeficient Mouse Model for Oncology Research 97

Other Significant Developments 98

Apr 25, 2018: Extending Biomarker Sensitivity with the Quanterix Simoa HD-1 98

Mar 08, 2018: Charles River Laboratories Makes Expansions to Global Biologics Infrastructure 99

Feb 21, 2018: Charles River Laboratories Announces New Tumor Model Compendium 100

Dec 06, 2017: Charles River Adds ERS License to CRISPR/Cas9 Service Offering 101

May 16, 2017: Charles River Laboratories Announces Updates to Oncology Business 102

Appendix 103

Methodology 103

About GlobalData 103

Contact Us 103

Disclaimer 103


List Of Figure

List of Figures

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Charles River Laboratories International Inc, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Charles River Laboratories International Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Charles River Laboratories International Inc, Medical Devices Deals, 2012 to YTD 2018 12

Charles River Laboratories International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

WIL Research Acquires Pharma Services Business Of Ricerca Biosciences 17

KPI Therapeutics Raises USD1.6 Million in Venture Financing 18

Charles River Labs and Distributed Bio Enter into Partnership 19

HemaCare and Charles River Laboratories Enter into Partnership 20

Inscopix Enters into Partnership with Brains On-Line 21

Nimbus Therapeutics Enters into Agreement with Charles River Laboratories International 22

Charles River Laboratories International Expands its Agreement with Chiesi Farmaceutici 23

Charles River Laboratories International Extends Agreement with Genentech 24

Charles River Labs Enters into Agreement with Tri-Institutional Therapeutics Discovery Institute 25

Moderna Therapeutics Enters into Agreement with Charles River Labs 26

Charles River Labs Enters into Agreement with BioMotiv 27

Eisai Extends Research Agreement with Charles River Labs 28

Charles River Labs Expands Agreement with Michael J. Fox Foundation for Parkinson's Research 29

Charles River Labs Enters into Agreement with Antabio 30

Charles River Labs Enters into Agreement with Pcovery 31

Charles River Labs Enters into Agreement with British Columbia Cancer Agency 32

Charles River Lab Extends Co-Development Agreement with CHDI Foundation 33

BioFocus Enters Into Drug Discovery Agreement With Boehringer Ingelheim 34

MPI Research Enters Into Agreement With inviCRO And 3D Imaging For Drug Discovery And Development 35

BioFocus Extends Agreement With Michael J. Fox Foundation For Parkinson's Disease 36

Applied StemCell Enters Into Distribution Agreement With Charles River Labs For Genetically Modified Targatt Mouse 37

BioFocus Enters Into Agreement With ChanTest 38

Charles River Labs Expands its Agreement with AstraZeneca 39

Ono Pharma Enters Into Discovery Agreement With BioFocus For CNS Drugs 40

Activiomics Enters Into Drug Discovery Agreement With BioFocus 41

Ono Pharma Enters Into Drug Discovery Agreement With BioFocus 42

Almirall Enters Into Integrated Drug Discovery Collaboration With BioFocus 43

EMD Millipore Enters Into Licensing Agreement With Charles River Labs For TrueSpike Technology 44

Charles River Laboratories International Plans to Raise Funds in Public Offering of Securities 45

Charles River Labs to Invest USD10 Million in BioMotiv 46

Charles River Lab Raises USD500 Million in Private Placement of 5.5% Senior Notes Due 2026 47

Charles River Laboratories Acquires MPI Research for USD800 Million 48

Charles River Labs Acquires KWS BioTest for USD24.3 Million 50

Charles River Laboratories Acquires Brains On-Line 51

Quotient Clinical Acquires QS Pharma from Charles River Labs 52

Charles River Laboratories Acquires Agilux Laboratories for USD64.9 Million 53

Charles River Labs Acquires Blue Stream Labs 54

Charles River Laboratories Acquires WIL Research for USD604.8 Million 55

Charles River Labs Acquires Oncotest 57

Charles River Labs Acquires ChanTest from Ampersand Capital for USD59.2 Million 58

MPI Research Acquired Jasper Clinic, Clinical Research Organization 59

Charles River Laboratories Acquires VivoPath 60

Charles River Labs Completes Acquisition Of BioFocus And Argenta Discovery From Galapagos For USD191.8 Million 61

Charles River Labs Acquires Brass 63

Charles River Labs Completes Acquisition Of 75% Stake In Vital River Labs For USD 27 Million 64

Charles River Plans Sale Of The Company 65

Charles River Laboratories International Inc, Key Competitors 66

Charles River Laboratories International Inc, Key Employees 67

Charles River Laboratories International Inc, Subsidiaries 69

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Charles River Laboratories International Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.